H101 + tirilizumab

H101 + tirilizumab is an investigational combination therapy composed of two agents: - **H101** is a recombinant human adenovirus type 5 oncolytic virus developed to selectively replicate in and lyse tumor cells with dysfunctional p53 pathways. It induces direct oncolysis and stimulates antitumor immune responses. - **Tirilizumab** is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, functioning as an immune checkpoint inhibitor to enhance T-cell mediated antitumor activity. The combination aims to synergistically improve anticancer efficacy by combining the direct tumor lysis and immunogenic effects of H101 with the immune activation provided by PD-1 blockade via tirilizumab. This approach is being explored primarily for solid tumors, including advanced or metastatic cancers.